Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Cited by (1,276)

Items 701–800 of 1,276

1. Cell‐Active, Irreversible Covalent Inhibitors Targeting a Surface‐Exposed Non‐Catalytic Lysine on Aurora a Kinase by Using Squarate Chemistry
   Zuqin Wang, Xuan Wang, Yong Li, Peishan Li, Shengjie Huang, Peng Chen, Guanghui Tang, Xiaotong Ding, Zhang Zhang, Zhi‐Min Zhang et al. · 2025 · Angewandte Chemie International Edition
2. Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
   H. Huber, Simone Edenhofer, Sven Estenfelder, Stephan Stilgenbauer · 2017 · OncoTargets and Therapy
3. Advances in Classification and Treatment of Non-Hodgkin Lymphoma
   Simon A. Rule, Sophie Johns · 2020 · The Cancer Journal
4. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton’s Tyrosine Kinase Inhibitors
   Meghan C. Thompson, Anthony R. Mato · 2021 · Hematology/Oncology Clinics of North America
5. Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
   Asim Najmi, Neelaveni Thangavel, Anugeetha Thacheril Mohanan, Marwa M. Qadri, Mohammed Albratty, Safeena Eranhiyil Ashraf, Safaa Fathy Saleh, Maryam Nayeem, Syam Mohan · 2023 · Pharmaceuticals
6. The molecular map of CLL and Richter's syndrome
   Amit Sud, Erin Michelle Parry, Catherine J. Wu · 2024 · Seminars in Hematology
7. Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review
   Andrea Visentin, Sara Frazzetto, Livio Trentin, Annalisa Chiarenza · 2024 · Cancers
8. Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed
   Alberto Fresa, Idanna Innocenti, Annamaria Tomasso, Luca Stirparo, Antonio Mosca, Francesco Iadevaia, Francesco Autore, Paolo Ghia, Luca Laurenti · 2024 · Cancers
9. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies
   Yang Zhou, Jibo Kang, Xiaoyun Lu · 2024 · Journal of Medicinal Chemistry
10. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma
    Allison Claire Rosenthal · 2017 · Current Hematologic Malignancy Reports
11. Advances in Lymphoma Molecular Diagnostics
    Igor Age Kos, Lorenz Thurner, Joerg Thomas Bittenbring, Konstantinos Christofyllakis, Dominic Kaddu‐Mulindwa · 2021 · Diagnostics
12. Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways
    Atefe Rahmati, Alireza Mafi, Omid Vakili, Firooze Soleymani, Zahra Alishahi, Sheida Yahyazadeh, Yasaman Gholinezhad, Malihe Rezaee, Thomas Patrick Johnston, Amirhossein Sahebkar · 2023 · Annals of Hematology
13. Fluorinated derivatives of 2-azinyl-4-(4-aminophenyl)quinazolines: Synthesis and photophysical properties
    Alexandra E. Kopotilova, Мaria I. Valieva, Еkaterina S. Starnovskaya et al. · 2023 · Journal of Photochemistry and Photobiology A Chemistry
14. Ibrutinib: from bench side to clinical implications
    Davide Grisafi, Alessandra Maestro, Camilla Grumi, L. Piazzoni, Giampaolo Tirone, Walter Fiore, Roberto Tessari, Valeria Gianardi, Milo Gatti, Francesca Tasca et al. · 2015 · Medical Oncology
15. Emerging immunological drugs for chronic lymphocytic leukemia
    Pawel J. Robak, Piotr Smolewski, Tadeusz Robak · 2015 · Expert Opinion on Emerging Drugs
16. Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap
    Aparna Lakshmanan, John C. Byrd · 2017 · Cancer Discovery
17. Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia
    Francesco Forconi, Stuart Lanham, Giorgia Chiodin · 2022 · Cancers
18. Dynamic Allostery in PLCγ1 and Its Modulation by a Cancer Mutation Revealed by MD Simulation and NMR
    Hans Koss, Tom D. Bunney, Diego Esposito, Marta Martins, Matilda Katan, Paul C. Driscoll · 2018 · Biophysical Journal
19. Streamlining SuFEx Inhibitor Development: A Unified Approach Using Photolabile and Orthogonal Sulfinate Protecting Groups
    Twinkle I. Patel, Malik Williams, Yumeng Chi, Ramkrishna Laha, Matthew J. Moschitto · 2025 · Angewandte Chemie International Edition
20. Computational approaches to druggable site identification: Current status and future perspective
    Anqi Lin, Zhirou Zhang, Aimin Jiang, Kexin Li, Ying Shi, Hong Yang, Jian Zhang, Rongrong Liu, Yaxuan Wang, Antonino Glaviano et al. · 2025 · Acta Pharmaceutica Sinica B
21. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Gaurav Varma, Tyler Paul Johnson, Ranjana H. Advani · 2016 · PubMed
22. B cell receptor inhibition as a target for CLL therapy
    Deepa Jeyakumar, Susan Mary O'Brien · 2016 · Best Practice & Research Clinical Haematology
23. The safety of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia
    Phu Ngoc Tran, Susan Mary O'Brien · 2017 · Expert Opinion on Drug Safety
24. Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms
    Megan S. Lim, Nathanael G. Bailey, Rebecca L. King, Miguel Angel Piris · 2019 · American Journal of Clinical Pathology
25. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
    Giorgia Chiodin, Samantha Drennan, Enrica Antonia Martino, Laura Ondrišová, Isla Henderson, Luis Del Rio, Ian Tracy, Annalisa D’Avola, Helen Parker, Silvia Bonfiglio et al. · 2022 · Blood Advances
26. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies
    Isaias Hernández-Verdín, Andrea Morales-Martínez, Khê Hoang‐Xuan, Agustí Alentorn · 2022 · Current Opinion in Neurology
27. Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
    Shih‐Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Sheila Waters, Jeffery Lorne Kutok et al. · 2023 · Clinical Cancer Research
28. Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD
    Philip A. Thompson, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Sa A. Wang, Jeffrey L. Jorgensen, Tapan Mahendra Kadia, Prithviraj Bose et al. · 2023 · Leukemia
29. mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia
    Natasha Malik, Jodie Hay, Hassan N. B. Almuhanna, Karen M. Dunn, Jamie Lees, Jennifer E. Cassels, Jiatian Li, Rinako Nakagawa, Owen James Sansom, Alison M. Michie · 2023 · Leukemia
30. Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?
    Othman Al‐Sawaf, Matthew Steven Davids · 2023 · Clinical Cancer Research
31. Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
    Juanita Suzanne Lopez, Sam Harris, Desam Roda, Timothy A. Yap · 2015 · Translational Oncogenomics
32. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise
    Foluso Nelson Ogunleye, Alexander Glick, Michael Stender, Ishmael A. Jaiyesimi · 2015 · Clinical Lymphoma Myeloma & Leukemia
33. Magic pills: new oral drugs to treat chronic lymphocytic leukemia
    Candida Vitale, Valentina Griggio, Maria Todaro, Chiara Salvetti, Mario Boccadoro, Marta Coscia · 2017 · Expert Opinion on Pharmacotherapy
34. Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
    Lauren Kelly Shea, Fady M. Mikhail, Andres Forero · 2017 · Clinical Case Reports
35. Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL
    Shanmugapriya Thangavadivel, John C. Byrd · 2019 · Cancer Discovery
36. Mantle Cell Lymphoma
    Benjamin T. Diamond, Anita Ashok Kumar · 2019 · Hematology/Oncology Clinics of North America
37. Promises and pitfalls of targeted agents in chronic lymphocytic leukemia
    Thomas Eliot Lew, Mary Ann Anderson, John Francis Seymour · 2020 · Cancer Drug Resistance
38. Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far
    Lauren Held, Chloe Siu, Mazyar S. Shadman · 2021 · Expert Opinion on Pharmacotherapy
39. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia
    Masa Lasica, Constantine Si Lun Tam · 2021 · Hematology/Oncology Clinics of North America
40. Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival
    Ti’ara L. Griffen, Eric B. Dammer, Courtney Denise Dill, Kaylin Carey, Corey D. Young, Sha’Kayla K. Nunez, Adaugo Q. Ohandjo, Steven Mitchell Kornblau, James W. Lillard · 2021 · BMC Medical Genomics
41. miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-κb signaling pathway in mantle cell lymphoma
    Jingjing Yuan, Qing Hua Zhang, Shengsheng Wu, Suran Yan, Ran Zhao, Yajuan Sun, Xiaoxu Tian, Keshu Zhou · 2021 · Experimental Hematology
42. The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance
    Raji E. Joseph, Jacques Lowe, D. Bruce Fulton, John R. Engen, Thomas E. Wales, Amy Hamilton Andreotti · 2021 · Journal of Molecular Biology
43. Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells
    Weam Othman Elbezanti, Omar S. Al‐Odat, Robert J. Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda et al. · 2022 · Frontiers in Pharmacology
44. Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability in vitro and in vivo
    Yonghui Sun, Zimo Yang, Zhimin Zhang, Zhen Li, Liubin Guo, Hao Pan, Xin Luo, Dongzhou Jeffrey Liu, Yu Rao · 2023 · RSC Medicinal Chemistry
45. Catalog of genetic progression of human cancers: non-Hodgkin lymphoma
    Csaba Bödör, Lilla Reiniger · 2016 · Cancer and Metastasis Reviews
46. Targeted Therapy of CLL
    Othman Al‐Sawaf, Kirsten Fischer, Barbara F. Eichhorst, Michael J. Hallek · 2016 · Oncology Research and Treatment
47. Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia
    Francesca Arruga, Silvia Deaglio · 2017 · Handbook of experimental pharmacology
48. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia
    Georg Lenz · 2017 · Journal of Clinical Oncology
49. Pathways towards indolent B-cell lymphoma — Etiology and therapeutic strategies
    Michiel van den Brand, Blanca Scheijen, Corine J. Hess, J. Han van Krieken, Patricia J.T.A. Groenen · 2017 · Blood Reviews
50. Progress on Small-Molecule Proteolysis-Targeting Chimeras
    Wenhai Huang, Beibei Wang, Zhimin Zhang, Chixiao Zhang, Shenxin Zeng, Zhengrong Shen · 2019 · Future Medicinal Chemistry
51. Characterisation of molecular mechanisms for PLCγ2 disease-linked variants
    Bunney, Tom D., Kampyli, Charis, Gregory, Ashley, Katan, Matilda · 2024 · Advances in Biological Regulation
52. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro
    Narjis Fatima, Yandong Shen, Kyle R. Crassini et al. · 2024 · Leukemia & lymphoma/Leukemia and lymphoma
53. Impact of leukemia-associated macrophages on the progression and therapy response of chronic lymphocytic leukemia
    Hendrik Jestrabek, Viktoria Kohlhas, Michael J. Hallek · 2024 · Leukemia Research
54. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib
    Hana Dostálová, Vladimı́r Kryštof · 2024 · Hematological Oncology
55. Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy
    María José Fernández, Eunice Kim, Cancan Zhang, Tuyen T. Yankama, Gottfried von Keudell, David J. Sermer, Caroline Mejías-De Jesús, Aarti H. Asnani · 2024 · The Oncologist
56. IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
    Alberto J. Arribas, Eleonora Cannas, Giulio Sartori, Francesca Guidetti, Luciano Cascione, Sara Napoli, Gabriela Forestieri, Federica Fuzio, Emma Pesenti, Chiara Tarantelli et al. · 2026 · Blood
57. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents
    Joseph J. Maly, James Stewart Blachly · 2016 · Current Hematologic Malignancy Reports
58. An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases
    Lisa J. Worrillow, Praveen Baskaran, Matthew A. Care, Abraham Mullasseril Varghese, Talha Munir, Paul Evans, Sheila J.M. O’Connor, Andy C. Rawstron, Lee D. Hazelwood, Reuben M. Tooze et al. · 2016 · Oncogene
59. Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review
    Paulina Stefaniuk, Julia Onyszczuk, Agnieszka Szymczyk, Monika Podhorecka · 2021 · Cancer Management and Research
60. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
    Javier L Munoz, Jonas Paludo, Shayna Sarosiek, Jorge Julio Castillo · 2022 · Cells
61. The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
    Tingyu Cao, Zengguang Wang, Xiaodong Zhu · 2022 · Journal of Inflammation Research
62. BTKbase, Bruton Tyrosine Kinase Variant Database in X-Linked Agammaglobulinemia: Looking Back and Ahead
    Gerard C. P. Schaafsma, Jouni Väliaho, Qing Wang, Anna Berglöf, Rula Zain, C. I. Edvard Smith, Mauno Vihinen · 2023 · Human Mutation
63. Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
    Κώστας Σταματόπουλος, Šárka Pavlová, Othman Al‐Sawaf, Thomas Chatzikonstantinou, Christina Karamanidou, Gianluca Gaïdano, Florence Cymbalista, Arnon Philip Kater, Andy C. Rawstron, Lydia Scarfò et al. · 2024 · HemaSphere
64. A fresh look at covalent BTK inhibitor resistance
    Lindsey Elizabeth Roeker · 2024 · Blood
65. Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia
    Wael Mossad Gamal, Melanie Mediavilla-Varela, Vishaal Kunta, Eva Sahakian, Javier A. Pinilla-Ibarz · 2025 · Frontiers in Cell and Developmental Biology
66. Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia
    Petra Langerbeins, Carolin Groß-Ophoff-Müller, Carmen Herling · 2016 · Oncology Research and Treatment
67. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge
    Mohamed A. Kharfan‐Dabaja, Jessica El‐Asmar, Farrukh Tauseef Awan, Mehdi Hamadani, Ernesto Ayala · 2016 · Best Practice & Research Clinical Haematology
68. “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
    Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin · 2016 · Mediterranean Journal of Hematology and Infectious Diseases
69. Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro‐environmental dialogue
    Elisa Göckeritz, Verena Vondey, Anna Guastafierro, Maja Pizevska, Floyd Hassenrück, Lars Neumann, Michael J. Hallek, Günter Krause · 2017 · British Journal of Haematology
70. Ibrutinib: A narrative drug review
    Nikita Mehra, Bhausaheb Pandurang Bagal, PriteshNaresh Munot, Sumeet Prakash Mirgh · 2020 · Cancer Research Statistics and Treatment
71. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax
    Ambrus Gángó, Richárd Kiss, Péter Farkas, Eid Hanna, Judit Demeter, Beáta Deák, Dóra Lévai, Lili Kotmayer, Donát Alpár, András Matolcsy et al. · 2021 · Pathology
72. Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia
    Elisa Albi, Antonella Capasso, Luana Schiattone, Paolo Ghia, Lydia Scarfò · 2022 · Seminars in Cancer Biology
73. A mechanistic study of thiol addition to N -acryloylpiperidine
    Sarah K. I. Watt, Janique G. Charlebois, Christopher N. Rowley · 2023 · Organic & Biomolecular Chemistry
74. Ibrutinib for Mantle Cell Lymphoma
    David L. Tucker, Simon A. Rule · 2016 · Future Oncology
75. Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials
    Elżbieta Iskierka‐Jazdzewska, Tadeusz Robak · 2020 · Expert Opinion on Investigational Drugs
76. Sensitization to Drug Treatment in Precursor B-Cell Acute Lymphoblastic Leukemia Is Not Achieved by Stromal NF-κB Inhibition of Cell Adhesion but by Stromal PKC-Dependent Inhibition of ABC Transporters Activity
    Paola Fernanda Ruiz-Aparicio, Gloria Inés Uribe, Adriana Linares Ballesteros, Jean‐Paul Vernot · 2021 · Molecules
77. Chronic Lymphocytic Leukemia
    Farrukh Tauseef Awan, John C. Byrd · 2020 · Elsevier eBooks
78. Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
    Raji E. Joseph, Thomas E. Wales, Sandrine Jayne, Robert G. Britton, D. Bruce Fulton, John R. Engen, Martin J.S. Dyer, Amy Hamilton Andreotti · 2024 · eLife
79. Chronic Lymphocytic Leukemia
    Min Shi, Dragan Jevremović, Curtis A. Hanson · 2024
80. Strategy for cysteine-targeting covalent inhibitors screening using in-house database based LC-MS/MS and drug repurposing
    Xiaolan Hu, Jian‐Lin Wu, Quan He, Zhi‐Qi Xiong, Na Li · 2024 · Journal of Pharmaceutical Analysis
81. BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders
    Andrea Duminuco, Paola De Luca, Gaia Stanzione, Laura Anastasia Caruso, Giulio Lavenia, Salvatore Scarso, Bruno Garibaldi, Fanny Erika Palumbo, Calogero Vetro, Giuseppe A. Palumbo · 2026 · Biomolecules
82. Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression
    Lesley‐Ann Sutton, Richard Rosenquist · 2014 · Expert Review of Hematology
83. Molecular Diagnostics of Non-Hodgkin Lymphoma
    James P. Solomon, Maria E. Arcila · 2020 · The Cancer Journal
84. Genetics and epigenetics of CLL
    Pamella Paul, Georg Stüssi, Alessio Bruscaggin, Davide Rossi · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
85. Mécanismes de résistance aux traitements des cancers
    Delphine Fessart, Jacques Robert · 2023 · Bulletin du Cancer
86. Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
    Lavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, Johanne Uthus Hermansen, Norman L. Mack, Sibylle Ohl, Verena Kalter, Murat Iskar, Mathias Kalxdorf, Dennis Friedel et al. · 2025 · Nature Communications
87. Novel agents in mantle cell lymphoma
    David L. Tucker, Simon A. Rule · 2017 · Expert Review of Anticancer Therapy
88. Dissecting CLL through high-dimensional single-cell technologies
    Satyen Harish Gohil, Catherine J. Wu · 2019 · Blood
89. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL
    Burcu Aslan, Görkem Kısmalı, Lisa S. Chen, LaKesla R. Iles, Mikhila Mahendra, Michael D. Peoples, Mihai Gagea, Natalie Wall Fowlkes, Xiaofeng Zheng, Jing Wang et al. · 2021 · Blood Advances
90. Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
    Adrian G. Minson, Constantine Si Lun Tam, Michael John Dickinson, John Francis Seymour · 2022 · Cancers
91. Developing potent BTKC481S PROTACs for ibrutinib-resistant malignant lymphoma
    Yonghui Sun, Xin Luo, Zimo Yang, Wenxing Lv, Lixia Chen, Hua Li, Yu Rao · 2022 · Chinese Chemical Letters
92. Clinical and immunological features of an APLAID patient caused by a novel mutation in PLCG2
    Qi Peng, Dong Luo, Yi Yang, Yinghua Zhu, Qingming Luo, Huan Chen, Dapeng Chen, Zhongjun Zhou, Xiaomei Lu · 2023 · Frontiers in Immunology
93. Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia
    Steven T. Pals, Marie José Kersten, Marcel Spaargaren · 2016 · Best Practice & Research Clinical Haematology
94. Ibrutinib-resistant CLL: unwanted and unwonted!
    Daniel Mertens, Stephan Stilgenbauer · 2017 · Blood
95. MYD88 Mutations and Sensitivity to Ibrutinib Therapy
    Y. Lynn Wang · 2018 · Journal of Molecular Diagnostics
96. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia
    Kimon V. Argyropoulos, Maria Lia Palomba · 2018 · Hematology/Oncology Clinics of North America
97. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia
    Sarit E. Assouline, Lilian Amrein, Raquel S. Aloyz et al. · 2020 · Leukemia & lymphoma/Leukemia and lymphoma
98. Chronic lymphocytic leukemia in 2020: a surfeit of riches?
    Sameer Ashok Parikh, Robert Peter Gale, Neil E. Kay · 2020 · Leukemia
99. Novel synthetic drugs for the treatment of non-Hodgkin lymphoma
    Farheen Manji, Robert Puckrin, Douglas Allan Stewart · 2021 · Expert Opinion on Pharmacotherapy
100. Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
     Adam J. Linley, Laura I. Karydis, Anil K. Mondru, Annalisa D’Avola, Humood Al Shmrany, Silvia Cicconi, Rebecca C. Griffin, Francesco Forconi, Andrew R. Pettitt, Nagesh Kalakonda et al. · 2021 · Clinical Cancer Research